Radiology Journals
Radiology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Radiology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Radiology
        Angiography
        Basic Science
        CT/SPECT/PET
        Chest
        Economics of Medicine
        Gastrointestinal
        Interventional
        MRI
        Mammography
        Musculoskeletal
        Neuroradiology
        Nuclear Medicine
        PACS/ General
        Pediatric Radiology
        Popular Press
        Radiotherapy (XRT)
        Ultrasound
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Small hepatocellular carcinoma: Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?
Shibata T et al. - In a study to prospectively compare combined radiofrequency ablation and transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for treatment of small (3 cm) hepatocellular carcinomas (HCCs), it appears that combined radiofrequency ablation plus TACE and radiofrequency ablation alone have equivalent effectiveness for treatment of small HCCs, so the combination treatment may not be necessary.

Methods
  • 89 pts with 93 HCC nodules 0.8–3.0 cm in diameter were randomly treated with combined radiofrequency ablation and TACE (46 pts with 49 nodules) or with radiofrequency ablation alone (43 pts with 44 nodules).
  • Patients were followed up for 9–68 mos.
  • Rates of local tumor progression (LTP), overall survival (OS), local progression-free survival (PFS), and event-free survival (EFS) were evaluated by using the Kaplan-Meier method.

Results
  • 1-, 2-, 3-, and 4-yr rates of LTP, OS, local PFS, and recurrence-free survival were as follows: LTP rates were 14.4%, 17.6%, 17.6%, and 17.6%, respectively, in combined treatment group and 11.4%, 14.4%, 14.4%, and 14.4%, respectively, in radiofrequency ablation group.
  • OS rates were 100%, 100%, 84.8%, and 72.7%, respectively, in combined treatment group and 100%, 88.8%, 84.5%, and 74.0%, respectively, in radiofrequency ablation group.
  • Local PFS rates were 84.6%, 81.1%, 69.7%, and 55.8%, respectively, in combined treatment group and 88.4%, 74.1%, 74.1%, and 61.7%, respectively, in radiofrequency ablation group.
  • EFS rates were 71.3%, 59.9%, 48.8%, and 36.6%, respectively, in combined treatment group and 74.3%, 52.4%, 29.7%, and 29.7%, respectively, in radiofrequency ablation group.
[more...]
Sponsor

Read a Different Specialty

General Radiology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

General Radiology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.